Recordati Signs License Agreement With Nycomed

Recordati has signed a license agreement with Nycomed for the sales and marketing of silodosin in Italy. Nycomed will also co-market the product along with Recordati in Italy.

Silodosin is a new compound indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Reportedly, the marketing approval authorization (MAA) request for silodosin was submitted to the EMEA (European Medicines Agency) during November 2008, and approval is expected in the first half of 2010.

Giovanni, chairman and CEO of Recordati, said: “We are delighted to have Nycomed as our co-marketer in Italy for this new drug. I am confident that the contribution of Nycomed, an important international pharmaceutical company, will be fundamental to the success of this new therapeutic option in Italy.”